India has the world's largest TB laboratory network and a dedicated National TB Elimination Program (NTEP).

The NTEP has been working tirelessly to detect and treat TB patients, and the introduction of BPaLM is another key step in this fight.

India has approved a new, shorter treatment regimen for Multi-drug resistant tuberculosis (MDR-TB), marking a significant step towards the country's goal of eliminating TB by 2025.

- The new treatment, called BPaLM, combines four drugs: Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin.

- BPaLM is proven to be safer, more effective, and quicker than previous MDR-TB treatments, curing patients in just six months (compared to up to 20 months previously).

- The introduction of BPaLM is expected to significantly accelerate India's progress towards its ambitious goal of ending TB.

The government is committed to eliminating TB by 2025, five years ahead of the global target.

Click here to read more